Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrazole (4,3-A) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
The present invention is directed to pharmaceutical compositions comprising compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and the use of these compositions in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes.